Looking back on medical devices & supplies - specialty stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including STAAR Surgical (NASDAQ:STAA) and its peers.
STAAR Surgical (STAA) faces heavy China distributor risk, rising receivables, and premium valuation. Read here for a detailed investment analysis.
Detailed price information for Netflix Inc (NFLX-Q) from The Globe and Mail including charting and trades.
It was the subject of a recommendation upgrade from an analyst.
STAAR Surgical (STAA) shares rose 7% in Tuesday trading after Stifel upgraded the stock to buy from
Stifel upgraded STAAR Surgical to Buy, while raising its price target, citing China momentum, EVO+ mix and upside to 2026-27 estimates.
Analysts upgraded STAA, NFLX, SFIX, with ratings moving toward Buy or Neutral and mixed price-target changes.
STAAR Surgical (STAA) stock gains as Stifel upgrades the company to Buy, citing a compelling entry point and H2 2026 sales upside—especially in China. Read more here.
Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 6.3% in the afternoon session after the company announced that its board of directors authorized a share repurchase program of up to $50 million.
It has launched a $50 million share repurchase program.
It has launched a $50 million share repurchase program.
Detailed price information for Staar Surgical Company (STAA-Q) from The Globe and Mail including charting and trades.
(Updates with stock movement in first paragraph and headline.) STAAR Surgical (STAA) shares rose
STAAR Surgical (STAA) said Thursday its board approved a share repurchase program allowing the compa
LAKE FOREST, Calif., September 24, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock.
STAAR Surgical recently reported quarterly net sales of US$93.5 million, an increase of 111% year over year, driven largely by China where revenue more than doubled to US$52.3 million and helped swing the company to US$8.1 million in net income from a loss a year earlier. Alongside this earnings rebound, STAAR strengthened its leadership bench by appointing former CEO David Bailey as Chief Commercial Officer and Ben Park, Ph.D., as Chief Technology Officer, signaling a focus on accelerating...
Executive Changes Reframe STAAR Surgical After Turnaround Results STAAR Surgical (STAA) reported a sharp business turnaround, with net sales rising 111% year over year and net income reaching $8.1 million, helped by China now contributing more than half of revenue. That backdrop sets the stage for two fresh executive appointments at the ophthalmic device producer. These moves could shape how the recent performance is translated into longer term commercial and product decisions. On the market...
On August 12, STAAR Surgical (NASDAQ:STAA) reported results for the quarter ended July 3 that flipped the script from a year earlier. Net sales jumped 111% year over year to $93.5 million, and the company that lost money in the same quarter of 2025 turned in $8.1 million of net income instead. It is the […]
David Bailey has rejoined STAAR after participating in the successful campaign to block Alcon’s takeover of the company.
This is the newest page. Registered accounts read further back.